CoChat

Efficacy of Glimepiride for the Treatment of Diabetes Occurring During Glucocorticoid Therapy

Open access
Kasayama, Soji, Tanaka, Toshio, Hashimoto, Kunihiko, Koga, Masafumi, Kawase, Ichiro · 2002 · Diabetes Care
Cited by 28

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

lacenta growth factor (PlGF) is a close homolog of vascular endothelial growth factor (VEGF), shares receptors with VEGF, and stimulates angiogenesis (1).Intravitreous PlGF levels are elevated in proliferative diabetic retinopathy (PDR) (2), but the relationship between PlGF levels and VEGF levels or clinical activity remains unclear.We attempted to ascertain whether intravitreous PlGF levels correlate with VEGF levels or clinical activity in PDR.We assayed PlGF and VEGF levels in vitreous samples from 50 consecutive patients with PDR (31 patients) and macular hole (nondiabetic control subjects, 19 patients) who underwent pars plana vitrectomy.The PDR stage was classified as active (16 patients) if there were new preretinal capillaries and as quiescent (15 patients) if the vasoproliferation consisted of only large vessels (3, 4).Informed consent was obtained from each patient.The undiluted vitreous samples were collected during the vitrectomy before intraocular infusion.Vitreous PlGF and VEGF concentrations were measured using an enzyme-linked immunosorbent assay (ELISA) for PlGF and VEGF (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol.The total protein concentration of the vitreous humor was measured using a BCA protein assay kit (Pierce Chemical, Rockford, IL).The Mann-Whitney U test was used to compare vitreous concentrations of PlGF and VEGF.Spearman's rank correlation test was used to examine correlations.PlGF and VEGF levels (median range) in PDR (PlGF, 100.6 pg/ml, range 7.6 -1,038.6;VEGF 653.9 pg/ml, 9.0 -5,423.8)were significantly higher (P Ͼ 0.0001) than in the control (PlGF 7.0 pg/ ml, 7.0 -12.1;VEGF 9.0 pg/ml, 9.0 -10.0).Moreover, the differences remained highly significant (P Ͻ 0.0001) when the ratio of PlGF and VEGF to protein was considered (PlGF 14.6, 1.5-250.7 vs. 2.6, 1.1-4.1;VEGF 95.5, 2.0 -904.0 vs. 3.0, 1.4 -5.3) (4,5).The ratio of PlGF and VEGF to protein in active PDR patients was significantly higher than that in quiescent PDR patients (PlGF 33.5, 2.7-250.7 vs. 11.1, 1.5-35.8,P ϭ 0.0039; VEGF 130.1, 7.8 -904.0 vs. 73.9,2.0 -150.3,P ϭ 0.0328).Intravitreous PlGF levels significantly correlated with intravitreous VEGF levels in both PDR patients (r ϭ 0.824, P Ͻ 0.0001) and total subjects (r ϭ 0.857, P Ͻ 0.0001).Neovascularization is the most important event in PDR.PlGF stimulates angiogenesis in vivo (1).PlGF is detected in the fibrovascular membranes of PDR (2), and PlGF mRNA expression significantly increases in retina during diabetic retinopathy (6).In this study, intravitreous PlGF levels were significantly higher in active PDR than in quiescent PDR, suggesting that PlGF is involved in the developing stages of PDR.PlGF does not directly induce endothelial cell proliferation or vascular permeability but acts indirectly by potentiating the activity of VEGF (7,8).Genetic studies indicate a synergism between PlGF and VEGF in pathological angiogenesis (9).In the present study, intravitreous PlGF levels significantly correlated with VEGF levels.Taken together, these results suggest that PlGF might have a cooperative role with VEGF in the progression of PDR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.25.12.2359

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 28

Metadata

Authors
Kasayama, S., Tanaka, T., Hashimoto, K., Koga, M., & Kawase, I.
Venue
Diabetes Care
Published
2002-12-01
Volume
25
Issue
12
Pages
2359-2360
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2059596187
Cited by
28
References
1
FWCI
0.18
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Glimepiride for the Treatment of Diabetes Occurring During Glucocorticoid Therapy. https://app.cochat.ai/papers/10.2337/diacare.25.12.2359
The paper
Kasayama, S., Tanaka, T., Hashimoto, K., Koga, M., & Kawase, I. (2002). Efficacy of Glimepiride for the Treatment of Diabetes Occurring During Glucocorticoid Therapy. Diabetes Care. https://doi.org/10.2337/diacare.25.12.2359

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.